Zymeworks BC Inc.
Zymeworks is dedicated to developing novel medicines for patients with difficult-to-treat diseases, leveraging revolutionary technologies to engineer fit-for-purpose biotherapeutics. Their fully integrated R&D engine from target selection to pivotal studies is powered by world-class researchers aiming to discover, develop, and commercialize innovative agents globally in collaboration with partners. The company focuses on transforming areas of high unmet medical need, especially in oncology, with a growing pipeline supported by best-in-class antibody-drug conjugates and multispecific antibody therapeutics technology platforms.
Industries
Nr. of Employees
large (251-1000)
Zymeworks BC Inc.
Products
HER2-targeted bispecific antibody (clinical candidate)
A bispecific antibody therapeutic designed to target HER2-expressing tumors; advanced through clinical studies and included in regulatory filings.
Antibody-drug conjugate (ADC) candidate programs
ADC candidates incorporating cytotoxic payloads and targeted antibodies, evaluated in preclinical and early clinical studies.
Trispecific T cell engager therapeutic programs
Trispecific constructs designed to engage T cells and direct cytotoxic activity against tumor antigens; supported by preclinical poster presentations.
HER2-targeted bispecific antibody (clinical candidate)
A bispecific antibody therapeutic designed to target HER2-expressing tumors; advanced through clinical studies and included in regulatory filings.
Antibody-drug conjugate (ADC) candidate programs
ADC candidates incorporating cytotoxic payloads and targeted antibodies, evaluated in preclinical and early clinical studies.
Trispecific T cell engager therapeutic programs
Trispecific constructs designed to engage T cells and direct cytotoxic activity against tumor antigens; supported by preclinical poster presentations.
Services
Negotiation and execution of licensing agreements and collaborative partnerships for therapeutic development and commercialization.
Handling of requests for clinical trial information and provision of medical/clinical data to authorized requesters.
Negotiation and execution of licensing agreements and collaborative partnerships for therapeutic development and commercialization.
Handling of requests for clinical trial information and provision of medical/clinical data to authorized requesters.
Expertise Areas
- Multispecific antibody therapeutics
- Antibody-drug conjugate development
- Preclinical and translational research
- Clinical trial management (Phase 1–pivotal)
Key Technologies
- Antibody-drug conjugates (ADC)
- Bispecific and trispecific antibody engineering
- T cell engager platforms
- Preclinical in vivo models and translational assays